Disease-free survival | ||||||||
Oesophageal/GOJ adenocarcinoma | Gastric adenocarcinoma | |||||||
Covariate | N | Median DFS (months, 95 % CI) | Hazard ratio (95 % CI) | P -value | N | Median DFS (months, 95 % CI) | Hazard ratio (95 % CI) | P -value |
Elevated tumour markers | ||||||||
No | 24 | 12.2 (8.8–16.2) | 1.0 | 0.794 | 16 | 10.8 (5.0–13.7) | 1.0 | 0.081 |
Yes | 63 | 11.8 (8.4–13.6) | 1.07 (0.66–1.72) | 24 | 15.0 (10.6–24.8) | 0.56 (0.29–1.08) | ||
Differentiation | ||||||||
Poor | 107 | 12.3 (8.8–20.7) | 1.0 | <0.001 | 94 | 37.9 (21.5–71.8) | 1.0 | 0.020 |
Moderate/well | 92 | 85.9 (33.1 – NA) | 0.40 (0.27–0.58) | 47 | 99.2 (36.2 – NA) | 0.54 (0.32–0.91) | ||
Pathological T-stage | ||||||||
T0-2 | 112 | 111.7 (77.7 – NA) | 1.0 | <0.001 | 107 | 86.9 (51.4–99.6) | 1.0 | 0.010 |
T3/4 | 97 | 12.2 (8.7–18.0) | 2.89 (2.00–4.18) | 36 | 21.5 (12.7–40.5) | 1.91 (1.16–3.12) | ||
Pathological N-stage | ||||||||
N0 | 105 | 111.7 (77.7 – NA) | 1.0 | <0.001 | 72 | 87.1 (86.9 – NA) | 1.0 | <0.001 |
N1-3 | 105 | 11.8 (8.4–15.7) | 3.38 (2.32–4.94) | 71 | 21.1 (12.7 - 38.0) | 3.10 (1.89–5.10) | ||
Resection margin | ||||||||
R0 | 161 | 77.7 (26.1 – NA) | 1.0 | <0.001 | 135 | 71.8 (35.6–99.6) | 1.0 | 0.080 |
R1/R2 | 47 | 8.7 (7.0–14.8) | 2.87 (1.96–4.20) | 7 | 13.2 (0.3 – NA) | 2.13 (0.91–4.98) | ||
Presence of symptoms at time of relapse | ||||||||
No | 33 | 10.9 (7.9–14.8) | 1.0 | 0.793 | 13 | 11.5 (4.8–21.5) | 1.0 | 0.259 |
Yes | 67 | 11.8 (7.2–12.4) | 1.06 (0.70–1.61) | 34 | 13.2 (8.1–20.6) | 0.68 (0.35–1.32) | ||
Neoadjuvant, adjuvant or perioperative therapy | ||||||||
No | 33 | 140.0 (111.7 – NA) | 1.0 | 0.001 | 53 | 34.1 (13.1–87.1) | 1.0 | 0.100 |
Yes | 181 | 20.9 (14.3–27.2) | 3.57 (1.74–7.31) | 93 | 86.9 (41.7 – NA) | 0.67 (0.42–1.08) | ||
Overall survival | ||||||||
Oesophageal/GOJ adenocarcinoma | Gastric adenocarcinoma | |||||||
Covariate | N | Median OS (months, 95 % CI) | Hazard ratio (95 % CI) | P -value | N | Median OS (months, 95 % CI) | Hazard ratio (95 % CI) | P -value |
Elevated tumour markers | ||||||||
No | 24 | 28.8 (15.2–40.7) | 1.0 | 0.343 | 16 | 20.0 (9.6–29.1) | 1.0 | 0.842 |
Yes | 63 | 22.4 (14.9–31.5) | 1.28 (0.77–2.11) | 24 | 22.6 (15.9–34.4) | 0.91 (0.49–1.80) | ||
Differentiation | ||||||||
Poor | 107 | 21.5 (15.2–33.0) | 1.0 | <0.001 | 94 | 40.5 (28.5–86.9) | 1.0 | 0.011 |
Moderate/well | 92 | 85.9 (76.7 – NA) | 0.37 (0.25–0.55) | 47 | 99.2 (53.7 – NA) | 0.50 (0.29–0.85) | ||
Pathological T-stage | ||||||||
T0-2 | 112 | 111.7 (77.7 – NA) | 1.0 | <0.001 | 107 | 81.2 (53.9–99.6) | 1.0 | 0.002 |
T3/4 | 99 | 27.9 (14.9–35.2) | 2.96 (2.00–4.36) | 36 | 29.1 (17.2–40.5) | 2.19 (1.33–3.61) | ||
Pathological N-stage | ||||||||
N0 | 105 | 111.7 (77.7 – NA) | 1.0 | <0.001 | 72 | 87.1 (86.9 – NA) | 1.0 | <0.001 |
N1-3 | 105 | 25.1 (14.7–34.1) | 3.33 (2.23–4.97) | 71 | 28.5 (19.4–48.7) | 3.16 (1.90–5.26) | ||
Resection margin | ||||||||
R0 | 161 | 77.7 (51.9 - NA) | 1.0 | <0.001 | 135 | 81.2 (48.8–99.6) | 1.0 | 0.062 |
R1/R2 | 47 | 13.8 (8.6–36.1) | 2.83 (1.91–4.19) | 7 | 17.2 (0.3 - NA) | 2.25 (0.96–5.26) | ||
Type of relapse | ||||||||
None | 114 | 140.0 (111.7 – NA) | 1.0 | (<0.001) | 99 | 99.2 (63.9–110.5) | 1.0 | (<0.001) |
Local | 5 | 38.1 (23.8 – NA) | 3.72 (1.43–9.67) | 0.007 | 4 | 20.0 (17.2 - NA) | 5.61 (1.93–16.2) | 0.001 |
Distant | 79 | 19.4 (14.4–27.9) | 6.66 (4.25–10.4) | <0.001 | 37 | 20.9 (15.4–28.5) | 7.13 (4.17–12.2) | <0.001 |
Both | 14 | 26.3 (12.5 – NA) | 5.31 (2.55–11.1) | <0.001 | 6 | 23.1 (14.0 – NA) | 5.88 (2.39–14.5) | <0.001 |
Presence of symptoms at time of relapse | ||||||||
No | 33 | 26.3 (22.1–38.9) | 1.0 | 0.071 | 13 | 29.1 (15.4–53.7) | 1.0 | 0.137 |
Yes | 66 | 18.6 (13.2–28.4) | 1.52 (0.96–2.41) | 34 | 20.0 (14.7–26.9) | 1.68 (0.85–3.36) | ||
Neoadjuvant, adjuvant or perioperative therapy | ||||||||
No | 33 | 140 (111.7 – NA) | 1.0 | 0.006 | 53 | 34.4 (18.7–87.1) | 1.0 | 0.028 |
Yes | 181 | 39.8 (28.8–59.6) | 2.59 (1.31–5.14) | 93 | 86.9 (53.6 – NA) | 0.59 (0.37–0.94) |